No Detail Found!

Exploring Intravenous Immunoglobulin (IVIG) efficacy in the Treatment of COVID-19

Author(s)
Abdulgader H. Albar Biological Sciences Department, Faculty of Science, Microbiology, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Microbiology and Parasitology, Collage of Medicine, University of Jeddah, Jeddah, Saudi Arabia
Feras S. Bajaba Biological Sciences Department, Faculty of Science, Microbiology, King Abdulaziz University, Jeddah, Saudi Arabia; Biology Department, Faculty of Science, University of Jeddah, Jeddah, Saudi Arabia
Bassam O. Aljohany Biological Sciences Department, Faculty of Science, Microbiology, King Abdulaziz University, Jeddah, Saudi Arabia
Abstract
The management of COVID-19 and its associated problems has become exceedingly challenging. This disparity has prompted the investigation and utilization of available therapeutic options, including supportive interventions, immunomodulatory drugs, convalescent plasma transfusions, and antiviral treatments. Although several treatments have demonstrated efficacy in treating COVID-19, there is a growing emphasis on immunoglobulins, especially intravenous immunoglobulin (IVIG), as a valuable therapeutic option for moderate and severe cases of COVID-19. The application of IVIG in the management of COVID-19 is guided by the anti-inflammatory properties of the immunoglobulins. The principal pathophysiological observation in severe COVID-19 cases is hyperinflammation, marked by increased levels of interleukin (IL)-2, IL-6, IL-7, tumor necrosis factor-alpha, inducible protein, and interferon gamma, which signifies a cytokine cascade and cytokine release syndrome. One of them is IVIG, which is used against inflammatory, immune-mediated diseases or infectious diseases. Numerous studies assert that IVIG treatment cured COVID-19 patients. The use of IVIG as an adjuvant treatment for COVID-19 has shown encouraging outcomes. Its clinical efficacy is attributed to its immunomodulatory and anti-inflammatory effects. While this is so, there exists a need for further research on the clinical efficacy of IVIG, given the use of relatively small sample sizes in the clinical trials conducted so far. This review has to show the potency of IVIG as a treatment for COVID-19. Further, other challenges that limit the use of IVIG therapy in COVID-19 include issues of cost and safety concerns that need to be addressed.
Publication Details
Page(s) 101-112
DOI DOI not available
Published Journal: Bioscience Research, Volume: 22, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
COVID-19, COVID-19, SARS-CoV-2, IVIG, IVIG, Covid-19, IVIG Immunomodulation, IVIG Immunological mechanisms
References
Ali Y. M. .2021 .Lectin pathway mediates complement activation by SARS-CoV-2 proteins'. Front. Immunol, 12 : 714511.
Alshehri F. M.,Alharthi S. B.,Kilani I.,Alsubai A. H.,Ayoub S. M.,Fakieh M. H.,Alzahrani A. M.,Alghamdi A. K.,Aljabri A. M.,Ahmed M. M. .2023 .Comparative study of the factors affecting the Microbiota presence in the human nasal cavity after Covid-19 influence. Bioscience Research, 4 : 1081-1089.
Alwafi H. A.,Abuljadayel L. W.,Ali S. S.,Kotha S. B.,Alzahrani S. A.,Halawani M. M.,Mirza L. F.,ElShitany N. A. .2024 .Prevalence and predictors of Albar et al. post-COVID-19 syndrome across SARS-CoV-2 affected Saudi individuals: From acute infection to one year after recovery. Bioscience Research, 1 : 14-28.
Arias-Reyes N.,Zubieta-DeUrioste N.,Poma-Machicao F.,Aliaga-Raudan F.,Carvajal-Rodriguez M.,Dutschmann E.,Schneider-Gasser E.,Soliz Z.,Dang S.,Su G.,Jin X.,Nan L.,Ma Z.,Li D.,Lu R.,Ge H. A.,Rothan S. N.,Byrareddy S. N. .2020 .'Does the pathogenesis of SARCoV-2 virus decrease at high-altitude? Respir'. Physiol. Neurobiol, 103443 : 112470.
Afonso Barahona,A. F. Barahona,João C. M. .2016 .The Production Processes and Biological Effects of Intravenous Immunoglobulin'. , 6 : 15.
Bayry S.,Lacroix-Desmazes C.,Carbonneil N.,Misra V.,Donkova A.,Pashov A.,Chevailler L.,Mouthon B.,Weill P.,Bruneval M. D.,Kazatchkine S. V.,Kaveri S. V. .2003 .Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin'. Blood, 101 : 758-65.
Bok K.,Sitar S.,Graham B. S.,Mascola J. R. .2021 .'Accelerated COVID-19 vaccine development: milestones, lessons. Immunity, 54 : 1636-51.
Bongomin Kenneth,Ssebambulidde Kenneth .2021 .Adjunctive intravenous immunoglobulins (IVIg) for moderate-severe COVID-19: emerging therapeutic roles'. Curr. Med. Res. Opin., 37 : 903-05.
BRUTON .1952 .. Pediatrics, 9 : 722-28.
Cao ,Yong Xiong Taisheng,Li Taisheng .2021 .Corrigendum: High-dose intravenous immunoglobulin in severe Coronavirus disease 2019: A multicenter retrospective study in China'. , 12 : 671443.
Cohn E. J. and Strong L.E. .1946 .'Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids'. J Am Chem Soc, 68 : 459-75.
Coloretti Massimo,Girardis Massimo .2021 .Rationale for polyclonal intravenous immunoglobulin adjunctive therapy in Covid19 patients: Report of a structured multidisciplinary consensus'. Preprints. The Effectiveness of IVIG against COVID-19, : .
Díez J. M.,Romero C.,Gajardo R. .2020 .Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens'. Immunotherapy, 12 : 571-76.
Focosi Mario,Cruciani Mario .2022 .Efficacy of high-dose polyclonal intravenous immunoglobulin in COVID19: A systematic review'. Vaccines (Basel), 10 : 94.
Freire-Álvarez Félix,Gutiérrez Félix .2020 .-associated encephalitis successfully treated with combination therapy'. Clinical Infection in Practice, 7 : 100053.
Galeotti C.,Kaveri S. V.,Bayry J. .2017 .IVIGmediated effector functions in autoimmune and inflammatory diseases'. Int Immunol, 29 : 491-98.
Garcia Jao,Jarro Jao .2021 .Intravenous immunoglobulin in COVID-19 associated Guillain-Barré syndrome in pregnancy'. BMJ Case Rep, 14 : e242365.
Gharebaghi N.,Nejadrahim R.,Mousavi S. J.,Sadat-Ebrahimi S. R.,Hajizadeh R. .2020 .The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial'. BMC Infect Dis, 20 : 786.
Guo Xuefeng,Wang Zheng,Xiao Zheng .2018 .Adverse effects of immunoglobulin therapy', Front. , 9 : 1299.
Herth Felix J. F.,George Sakoulas,Haddad Fadi .2020 .Use of intravenous immunoglobulin (prevagen or octagam) for the treatment of COVID19: Retrospective case series'. , 99 : 1145-53.
Hooper John A. .2015 .The history and evolution of immunoglobulin products and their clinical indications'. , 2 : 181-94.
Huang Weixia,Li Wei Xu,Li Qiang,Chen and Liang .2021 .Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching'. Int. J. Infect. Dis., 105 : 525-31.
Kakavandi ,Maryam VaezJalali,Hajikhani Bahareh .2023 .'Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases'. Cell Communication and Signaling, 21 : 110.
Kolahchi Nima,Rezaei Nima .2021 .Potential therapeutic approach of intravenous immunoglobulin against COVID-19', Allergy Asthma Clin. , 17 : 105.
Kwapisz D.,Bogusławska and J. .2023 .Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients'. Biomed Pharmacother, 163 : 114851.
Lanza Giuseppe,Fiorentino Giuseppe .2020 .Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia'. IDCases, 21 : e00794.
Liu J.,Chen Y.,Li R.,Wu Z.,Xu Q.,Li Z.,Annane D.,Feng H.,Huang S.,Guo J.,Zhang L.,Ye X.,Zhu W.,Du H.,Wang T.,Chen L.,Wen Z.,Teboul J. L.,Chen D. .2021 .Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study. Clin Microbiol Infect, 27 : 1488-93.
Lotfi M.,Hamblin M. R.,Rezaei N. .2020 .'COVID19: Transmission, prevention, and potential therapeutic opportunities'. Clin Chim Acta, 508 : 254-66.
Mazeraud A.,Gonçalves B.,Aegerter P.,Mancusi L.,Rieu C.,Bozza F.,Sylla K.,Siami S.,Sharshar T. .2021 .Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial'. Trials, 22 : 170.
Mazeraud A.,Jamme M.,Mancusi R. L.,Latroche C.,Megarbane B.,Siami S.,Zarka J.,Moneger G.,Santoli F.,Argaud L.,Chillet P.,Bruel C.,Asfar P.,Beloncle F.,Reignier J.,Vinsonneau C.,Schimpf C.,Amour J.,Goulenok C.,Lemaitre C.,Rohaut B.,Mateu P.,Mourvillier B.,Declercq P. L.,Schwebel C.,Stoclin A.,Garnier M.,Madeux B.,Gaudry S.,Bailly K.,Lamer C.,Aegerter P.,Rieu C.,Sylla K.,Lucas B.,Sharshar T. .2022 .Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial'. Lancet Respir Med, 10 : 158-66.
Mohamed .2021 .'Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: A web-based survey'. PLoS The Effectiveness of IVIG against COVID-19 One, 16 : e0256110.
Muccioli Olivia J.,Henry Francesca,Bisulli Francesca,Neurol J. .2021 .Intravenous immunoglobulin therapy in COVID-19-related encephalopathy'. , 268 : 2671-75.
Nabih ,Heba K. .2021 .Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia'. Bull. Natl. Res. Cent., 45 : 46.
Novaretti M. C.,Dinardo C. L. .2011 .Immunoglobulin: production, mechanisms of action and formulations'. Rev Bras Hematol Hemoter, 33 : 377-82.
Poremba George,Sakoulas George .2021 .Intravenous immunoglobulin (IVIG) in treating non-ventilated COVID-19 patients with moderate to severe hypoxia is pharmacoeconomically favorable when appropriately targeted'. , : .
Pourahmad Bobak,Moazzami Nima,Rezaei Nima .2020 .Efficacy of plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients with COVID-19'. Clin. Med, 2 : 1407-11.
Raju T. N. .2006 .Emil Adolf von Behring and serum therapy for diphtheria'. Acta Paediatr, 95 : 258-9.
Rojas ,Diana M. Monsalve ,Díaz-Coronado Ruben D.,Mantilla Ruben D.,Juan-Manuel Anaya Ruben D. .2020 .Convalescent plasma in Covid-19: Possible mechanisms of action', Autoimmun. , 19 : 102554.
Sakoulas G.,Geriak M.,Kullar R.,Greenwood K. L.,Habib M.,Vyas A.,Ghafourian M.,Dintyala V. N. K.,Haddad F. .2019 .. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease, 2 : e0280.
Sapir T.,Blank M.,Shoenfeld Y.,Ann N Y Acad Sci Y. .2005 .Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss'. , 1051 : 743-78.
Satarker S.,Nampoothiri M. .2020 .'Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2'. Arch Med Res, 51 : 482-91.
Shao ,Ming Wu .2020 .'Clinical efficacy of Albar et al. intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin. Transl. Immunology, 9 : e1192.
Shereen M.,Khan S.,Kazmi A.,Bashir N.,Siddique R. .2020 .'COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses'. J. Adv. Res, 24 : 91-98.
Tabarsi H.,Jamaati S.,Haseli M.,Marjani A.,Moniri Z.,Abtahian A.,Dastan S.,Yousefian R.,Eskandari A.,Saffaei F.,Monjazebi A.,Vahedi F.,Dastan F. .2021 .'Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial'. Int Immunopharmacol, 90 : 107205.
Tzilas V.,Manali E.,Papiris S.,Bouros D. .2020 .Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool'. , 99 : 1087-89.
Wan ,Yusen Zhou Fang,Li Fang,Virol J. .2020 .'Molecular mechanism for antibodydependent enhancement of Coronavirus entry'. , 94 : .
Wu ,Yi-Chi ,Chan Yu-Jiun .2020 .The outbreak of COVID-19: An overview'. J. Chin. Med, 83 : 217-20.
Xiang ,Huai-Rong ,Wen-Wen Luo,Qi-Zhi Zhang Luo,Wen-Xing Peng Luo .2021 .Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis'. Int. Immunopharmacol., 96 : 107732.
Yadav R.,Chaudhary J. K.,Jain N.,Chaudhary P. K.,Khanra S.,Dhamija P.,Sharma A.,Kumar A.,Handu S. .2021 .'Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2. , 10 : .
Zhou P.,Yang X. L.,Wang X. G.,Hu B.,Zhang L.,Si H. R.,Zhu Y.,Li B.,Huang C. L.,Chen H. D.,Chen J.,Luo Y.,Guo H.,Jiang R. D.,Liu M. Q.,Chen Y.,Shen X. R.,Wang X.,Zheng X. S.,Zhao K.,Chen Q. J.,Deng F.,Liu L. L.,Yan B.,Zhan F. X.,Wang Y. Y.,Xiao G. F.,Shi Z. L. .2020 .'A pneumonia outbreak associated with a new coronavirus of probable bat origin'. Nature, 579 : 270-73.
0

Citations

0

Downloads

76

Views